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 Introduction 
 Aplastic anemia (AA) is a rare disease characterized 
by the diminished or absent hematopoietic precursors 
in the bone marrow due to injury to the pluripotent
hematopoietic stem cell. AA is successfully treated by 
bone marrow transplantation (BMT) or by immuno-
suppressive therapy (IST), usually including anti-thy-
mocyte globulin (ATG) and cyclosporine  [1] . Response 
rates in the range of 60–80% after IST suggest that in the 
majority of cases AA is an autoimmune disease  [2] . In 
contrast to many other autoimmune diseases, the tar-
get of autoimmunity has so far not been elucidated, al-
though some candidate genes have been suggested  [3] . 
Analysis of T lymphocytes in AA patients has identified 
a pathogenetic role for both CD8 and CD4 T cells  [4, 5] . 
Recent studies have also described antibodies against a 
variety of auto-antigens in AA patients, although their 
role in the pathogenesis of the disease remains unclear 
 [6] .
 A clinical picture resembling AA may occur in pa-
tients with hematological or solid malignancies after 
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 Abstract 
 Background/Aims: Antibodies against carbonic anhydrase 
(CA) have been detected in patients with an aplastic anemia 
(AA)-like syndrome after autologous stem cell transplanta-
tion.  Methods: We analyzed sera of 53 bona fide AA patients 
before and after treatment with anti-thymocyte globulin 
(ATG) or bone marrow transplantation for the presence of 
anti-CA antibodies.  Results: Anti-CA antibodies were de-
tected in 20 patients (38%) and were associated with older 
age at diagnosis of AA. Antibody-positive patients showed 
poor response to ATG treatment (complete response 14%) 
and inferior long-term survival (36% at 10 years), when com-
pared to antibody-negative patients (complete response 
and 10-year survival both 64%). Two thirds of patients with 
antibodies at diagnosis of AA became antibody negative af-
ter treatment with ATG. Clearance of the antibody did not 
appear to be associated with hematological improvement. 
 Conclusion: Antibodies against CA are detected frequently 
at diagnosis of AA, and their presence identifies a subset of 
patients with poor response to immunosuppressive treat-
ment.  Copyright © 2012 S. Karger AG, Basel 
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high-dose chemotherapy and autologous stem cell trans-
plantation. Recent work has demonstrated that antibod-
ies against carbonic anhydrase (CA) may be found in a 
significant portion of these patients. Interestingly, devel-
opment of anti-CA antibodies also correlated with re-
gression of the underlying malignant disease, indicating 
that an autoimmune process may contribute to tumor 
control  [7, 8] .
 Antibodies against CA have so far not been described 
in patients with AA. We aimed to elucidate the incidence 
and the prognostic significance of anti-CA antibodies in 
53 AA patients treated at our institution with ATG or 
BMT for AA  [9] .
 Patients and Methods 
 Patients 
 Serum samples of patients with AA were collected before and 
after treatment with ATG or BMT and stored at –80  °  C until anal-
ysis. Patients underwent treatment with horse ATG plus cyclospo-
rine or sibling donor BMT at a single institution as described pre-
viously  [10] . Severity of AA and response to treatment were clas-
sified according to established guidelines  [11, 12] . Patients gave 
written informed consent to the analysis, and the study was ap-
proved by the local institutional review board.
 Detection of Anti-CA Antibodies 
 The presence of antibodies against 40 ng of commercial hu-
man CA I (purchased from Sigma-Aldrich Corporation, St. Lou-
is, Mo., USA) was analyzed by Western blotting of patients’ or 
healthy donors’ sera which were diluted 500 times. Bands were 
quantified using the ImageJ software (http://rsb.info.nih.gov/ij). 
A patient previously characterized as strongly antibody positive 
 [7] was used as internal reference in each batch of serum samples 
analyzed (defined arbitrarily as 1 unit). A population of healthy 
control donor sera was used to establish the lower reference range 
cutoff (mean + 2 standard deviations).
 HLA Typing 
 Patients from which cryopreserved bone marrow cells were 
available (n = 42) were typed for the presence of HLA-DR * 15
using a commercial kit employing sequence-specific primers 
(OneLambda, Canoga Park, Calif., USA).
 Statistics 
 Characteristics of patients with or without anti-CA antibodies 
were compared by Mann-Whitney U test for continuous or Pear-
son’s   2 test for categorical variables. The impact of antibody pos-
itivity on survival was analyzed by Kaplan-Meier analysis. Cumu-
lative incidences of patients responding to treatment were calcu-
lated treating death in the absence of response as a competing risk. 
All p values are two-sided, and were considered significant if 
 ! 0.05.
 Results 
 Fifty-three patients treated for AA between 1980 and 
2002 at our institution with ATG (n = 39) or BMT (n = 14) 
were included in the analysis. Median follow-up of surviv-
ing patients in this cohort was 17 years (range 11–24). Pre-
treatment sera were available in all patients. In the major-
ity of patients (n = 42), one or more posttreatment sera were 
also analyzed; they had been collected between 1 month 
and 12 years after initial therapy for AA. The median num-
ber of sera analyzed per patient was 5 (range 1–9).
 Antibodies against CA Are Frequent in
Patients with AA 
 Before initiation of treatment, antibodies against CA 
were detectable in 20 patients (38% of the population). 
Table 1.  Patient characteristics
Antibody– 
(n = 33)
Antibody+ 
(n = 20)
p
AA etiology
Idiopathic 30 (91) 17 (85) 0.39
Drug induced 2 (6) 0 
Benzene induced 0 2 (10)
Post-hepatitis 0 1 (5)
Post-EBV 1 (3) 0 
Disease severity
Non-severe AA 3 (9) 2 (10) 0.90
Severe AA 17 (52) 9 (45)
Very severe AA 13 (39) 9 (45)
HLA DR15 present 12/28 (43) 6/14 (43) 1.00
Blood counts at diagnosis, 109/l
Neutrophils
Median 0.238 0.199 0.89
Range 0–1.391 0.016–1.468
Reticulocytes
Median 13 6 0.49
Range 0–166 0–75
Platelets
Median 11 12 0.76
Range 2–95 3–124
First-line treatment
ATG 25 (76) 14 (70) 0.65
BMT 8 (24) 6 (30)
Patient sex
Male 14 (42) 9 (45) 0.85
Female 19 (58) 11 (55)
Patient age at diagnosis
Median 22 38 0.04
Range 2–63 4–73
Figures in parentheses indicate percentages.
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Characteristics of patients with and without detectable
anti-CA antibodies are summarized in  table  1 . Patient
gender, etiology of AA, and disease severity were not sig-
nificantly different between antibody-positive and anti-
body-negative patients. No difference was found in the fre-
quency of patients carrying HLA-DR * 15, a class II HLA 
antigen previously found to be overrepresented in AA  [13] . 
Anti-CA-positive patients were older at diagnosis of AA 
(median 38 years vs. 22 years in anti-CA-negative patients).
 In 10 of the patients carrying anti-CA antibodies be-
fore treatment (9 treated with ATG, 1 with BMT), follow-
up samples were available. In the patient treated with 
BMT, antibodies were no longer detectable  6 months
after transplantation. In the patients treated with ATG, no
clear picture emerged: 3 patients cleared the antibody
after ATG and attained hematological improvement 
(UPN 279, 350, 468). Notably, in the last patient, the anti-
body reappeared followed by AA relapse ( fig. 1 a and on-
line suppl. fig. 1; for all online suppl. material, see www.
karger.com/doi/10.1159/000338826). Three other patients 
became antibody-negative without hematological im-
provement (UPN 311, 331, 524). The remaining 3 patients 
achieved hematological improvement despite continuous 
positivity for anti-CA antibodies (UPN 569, 625, 646). 
Evolution of antibody positivity and hematological param-
eters are summarized in online supplementary figure 1.
 Survival and Response to Immunosuppressive 
Treatment Is Poor in Patients with Anti-CAA 
Antibodies 
 Of 39 patients treated with IST, 18 (46%) achieved
a complete response, and 12 (31%) a partial response, 
whereas 9 patients (23%) showed no improvement for a 
total response rate (CR + PR) of 77%. Analysis of antibody 
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 Fig. 1.  a Antibodies against CA detected with Western blot in a patient with AA at diagnosis (lane 1), and at 
different time points after treatment with ATG.  b Response rate to IST with ATG + cyclosporine in patients 
with or without anti-CA antibodies at diagnosis.  c Cumulative incidence of response to IST in patients with or 
without anti-CA antibodies.  d Overall survival in patients with or without anti-CA antibodies treated with IST. 
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positivity before treatment and response to immunosup-
pressive treatment showed an unexpected negative cor-
relation. While 16/25 (64%) antibody-negative patients 
achieved complete response to immunosuppressive treat-
ment, only 2/14 (14%) patients with detectable antibody 
before treatment responded completely. In contrast, the 
frequencies of patients showing no improvement to
IST were 3/25 (12%) for anti-CA-negative patients, and
6/14 (43%) for anti-CA-positive patients (overall p value = 
0.003;  fig.  1 b). Partial or complete responses were also 
achieved faster in patients without antibody (median time 
to response 3.6 months) than in patients with anti-CA an-
tibodies (median time to response 6 months;  fig. 1 c).
 The detrimental effect of anti-CA antibodies in pa-
tients treated with ATG was also evident from survival 
analysis, which showed a trend towards inferior long-
term survival of antibody-positive patients if treated with 
IST: 10-year survival after ATG treatment amounted to 
64  8 10% in antibody-negative versus only 36  8 13% in 
antibody-positive patients (p = 0.06;  fig. 1 d).
 Clonal Complications 
 Twelve of 39 patients developed a clonal complication 
after treatment with ATG. Eight patients developed par-
oxysmal nocturnal hemoglobinuria after treatment with 
ATG, 4/25 (16%) antibody-negative patients and 4/14 (29%) 
antibody-positive patients (p = 0.35). Five patients devel-
oped myelodysplastic syndrome: 2/25 (8%) antibody-neg-
ative and 3/14 (21%) antibody-positive patients (p = 0.23).
 Discussion 
 This is the first analysis of the incidence of antibodies 
against CA in patients with AA. CA is a protein that that 
catalyzes the interconversion of carbon dioxide and water 
to bicarbonate and protons, and is almost ubiquitously 
expressed. Anti-CA antibodies have been described in 
patients with connective tissue diseases such as lupus er-
ythematosus or Sjögren’s syndrome  [14, 15] . In lupus pa-
tients, IgG antibodies that suppress hematopoiesis have 
been described, although the target they recognize has 
not been elucidated so far  [16] .
 While AA is generally considered a T cell-mediated 
autoimmune disease, several recent studies have shown 
that AA patients frequently carry autoantibodies. Feng et 
al. [17] found antibodies against diazepam-binding in-
hibitor-related protein 1 (DRS-1) in 27/71 (38%) of pa-
tients with PNH+ AA and in 2/32 (6%) patients with 
PNH– AA. Response to IST was 100% in patients with 
anti-DRS-1 antibodies, but only 55% in patients without 
anti-DRS-1 antibodies. The same group later demon-
strated antibodies against moesin in 25/67 (37%) patients 
with AA. In contrast to antibodies against DRS-1, anti-
moesin antibodies were not associated with improved re-
sponse to immunosuppressive treatment  [18] . Most re-
cently, antibodies against heterogeneous nuclear ribonu-
cleoprotein (hnRNP) K were described in 85/273 (31%) 
AA patients. Response to IST was 87% in antibody-posi-
tive patients compared to only 46% in antibody-negative 
patients. Interestingly, in serial measurements before and 
after IST, antibody titers against hnRNP K remained 
strongly positive in patients irrespective of their response 
to treatment  [19] . The presence of these autoantibodies
in AA patients does not imply their involvement in the 
pathogenesis of the disease and may be an epiphenome-
non of the autoimmune process. Interestingly, however, 
an AA patient with multiple autoantibodies (including 
anti-DRS-1 and anti-moesin) was recently reported to 
have undergone successful treatment with the anti-
CD20-antibody rituximab after failure of IST with ATG 
and cyclosporine  [20] .
 The finding that anti-CA antibodies occur after au-
tologous stem cell transplantation in patients showing a 
clinical picture resembling AA prompted us to study an-
ti-CA antibodies in AA  [7] . We show that anti-CA anti-
bodies occur in untreated AA patients at a frequency of 
38%, which is comparable to the frequency of antibodies 
against DRS-1, moesin, or hnRNP K. In contrast to anti-
bodies previously detected in AA patients, presence of 
anti-CA antibodies was not associated with a better re-
sponse to IST. In contrast, patients carrying anti-CA an-
tibodies showed poor response to IST. Whether antibod-
ies against CA might serve as a predictive marker of pa-
tients with poor response to IST, which might benefit 
from alternative treatment strategies (i.e. stem cell trans-
plantation), will have to be assessed in future studies.
 In conclusion, we show that a significant proportion of 
AA patients carry antibodies against CA. Half of patients 
treated with IST become antibody negative after treat-
ment. No correlation was found between posttreatment 
antibodies and response, and response to IST was poor in 
anti-CA antibody-positive patients.
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